Published June 10, 2010 | Version v1
Journal article

Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers

  • 1. Department of Radiation Oncology, Tom Baker Cancer Center and University of Calgary, 1331 29 St NW, Calgary AB, T2N 4N2 (Canada)
  • 2. Department of Medical Physics, Saskatoon Cancer Center, 20 Campus Drive, Saskatoon SK, S7N 4H4 (Canada)
  • 3. Department of Radiation Oncology, Saskatoon Cancer Center, 20 Campus Drive, Saskatoon SK, S7N 4H4 (Canada)
  • 4. Department of Radiation Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton AB, T6G 1Z2 (Canada)
  • 5. Department of Radiation Oncology, Allan Blair Cancer Center, 4101 Dewdney Avenue, Regina SK, S4T 7T1 (Canada)

Description

Fiducial markers and daily electronic portal imaging (EPI) can reduce the risk of geographic miss in prostate cancer radiotherapy. The purpose of this study was to estimate CTV to PTV margin requirements, without and with the use of this image guidance strategy. 46 patients underwent placement of 3 radio-opaque fiducial markers prior to prostate RT. Daily pre-treatment EPIs were taken, and isocenter placement errors were corrected if they were ≥ 3 mm along the left-right or superior-inferior axes, and/or ≥ 2 mm along the anterior-posterior axis. During-treatment EPIs were then obtained to estimate intra-fraction motion. Without image guidance, margins of 0.57 cm, 0.79 cm and 0.77 cm, along the left-right, superior-inferior and anterior-posterior axes respectively, are required to give 95% probability of complete CTV coverage each day. With the above image guidance strategy, these margins can be reduced to 0.36 cm, 0.37 cm and 0.37 cm respectively. Correction of all isocenter placement errors, regardless of size, would permit minimal additional reduction in margins. Image guidance, using implanted fiducial markers and daily EPI, permits the use of narrower PTV margins without compromising coverage of the target, in the radiotherapy of prostate cancer

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-5-52; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896366

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
5
Journal Page Range
p. 52
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47029451
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BIOMEDICAL RADIOGRAPHY; ERRORS; FIDUCIAL MARKERS; IMAGES; LICENSES; NEOPLASMS; PLANNING; PROFITS; PROSTATE; RADIOTHERAPY
Descriptors DEC
BODY; DIAGNOSTIC TECHNIQUES; DISEASES; GLANDS; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c)2010 Skarsgard et al
Notes
PMCID: PMC2896366; PUBLISHER-ID: 1748-717X-5-52; PMID: 20537161; OAI: oai:pubmedcentral.nih.gov:2896366; licensee BioMed Central Ltd.